Share

    


Home / Search Results

Search Results

You searched for:

Medicare prior authorization requirements acts as a barrier to patients accessing necessary services and treatments, thus creating a need for reform.
A $1.5 trillion omnibus spending package for fiscal year 2022 was passed with broad bipartisan support in Congress and signed into law by President Biden on March 15, 2022.
On Aug. 4, the Centers for Medicare & Medicaid Services (CMS) released its 2021 Hospital Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (PFS) proposed rules.
On Sept. 27, ACCC provided comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed CY 2020 Outpatient Prospective Payment System (OPPS) and Physician Fee Schedule (PFS) rules.
Calendar year (CY) 2020 begins the transition in the Medicare physician fee schedule (PFS) payment system away from fee-for-service reimbursement, which is affected by the changing conversion factor, to a payment system that is set with potential changes related to budget neutrality.
Drug pricing reform and a thorough analysis of healthcare spending have been the focus of healthcare leadership across the country since early 2018.
In September 2018, the Association of Community Cancer Centers (ACCC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to both the 2019 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules. The arrival of autumn signals seasonal changes, but one constant is the policy implications of the proposed Medicare payment rules …
Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials (OEI-09-16-00410; 09/18) U.S. Department of Health and Human Services Office of Inspector General Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials Daniel R. Levinson Inspector General …
All eyes are on Congress in recent months with Affordable Care Act repeal and tax reform, but the real action—and consequential reimbursement decisions for ACCC cancer programs—is happening on the regulatory side.
While the 340B Program has grown, and reform has been widely debated by policymakers over the past decade, CMS’ rule proposes to fundamentally alter the program (notably a program that is not within CMS’ purview).